Welcome to LookChem.com Sign In|Join Free

CAS

  • or

107491-28-1

Post Buying Request

107491-28-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

107491-28-1 Usage

General Description

(BIPHENYL-4-SULFONYLAMINO)-ACETIC ACID, also known as sulindac, is a nonsteroidal anti-inflammatory drug (NSAID) that is used to reduce pain and inflammation in conditions such as arthritis. It works by inhibiting the production of prostaglandins, which are substances in the body that cause pain and inflammation. Sulindac is a sulfonamide derivative and has been shown to have anti-cancer properties, particularly in the prevention and treatment of colon cancer. It is typically used in combination with other medications to treat various conditions and is available in tablet form for oral administration. However, it can cause side effects such as gastrointestinal irritation, so caution should be taken when using this medication.

Check Digit Verification of cas no

The CAS Registry Mumber 107491-28-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,7,4,9 and 1 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 107491-28:
(8*1)+(7*0)+(6*7)+(5*4)+(4*9)+(3*1)+(2*2)+(1*8)=121
121 % 10 = 1
So 107491-28-1 is a valid CAS Registry Number.

107491-28-1Downstream Products

107491-28-1Relevant articles and documents

Target-activated prodrugs (TAPs) for the autoregulated inhibition of MMP12

Cobos-Correa, Amanda,Stein, Frank,Schultz, Carsten

supporting information, p. 653 - 657,5 (2020/08/31)

We describe a prodrug concept in which the target enzyme MMP12 produces its own inhibitor in a two-step activation procedure. By using an MMP12-specific peptide sequence and a known sulfonamide drug integrated in the backbone, the active inhibitor is released upon enzyme cleavage. In in vitro experiments, we present proof of concept that the activation proceeds with useful kinetics. The approach is highly selective over the closely related MMP8. If applied in vivo in the future, these prodrugs might release the active entity in a highly specific manner only at such sites where enzyme activity resides.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 107491-28-1